it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done..
cambridge's bluebird bio licenses delivery tech to novartis, gsk.
.
labour�s new study is based on freedom of information data from 95 english nhs trust..
richard lipton, md, director, montefiore headache center; edwin s. lowe professor and vice chairman of neurology, albert einstein college of medicine..